Abstract
Although most neurodegenerative diseases have been closely related to aberrant accumulation of aggregation-prone proteins in neurons, understanding their pathogenesis remains incomplete, and there is no treatment to delay the onset or slow the progression of many neurodegenerative diseases. The availability of induced pluripotent stem cells (iPSCs) in recapitulating the phenotypes of several late-onset neurodegenerative diseases marks the new era in in vitro modeling. The iPSC collection represents a unique and well-characterized resource to elucidate disease mechanisms in these diseases and provides a novel human stem cell platform for screening new candidate therapeutics. Modeling human diseases using iPSCs has created novel opportunities for both mechanistic studies as well as for the discovery of new disease therapies. In this review, we introduce iPSC-based disease modeling in neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. In addition, we discuss the implementation of iPSCs in drug discovery associated with some new techniques.
Similar content being viewed by others
References
Yang YM, Gupta SK, Kim KJ, Powers BE, Cerqueira A, Wainger BJ, Ngo HD, Rosowski KA, Schein PA, Ackeifi CA, Arvanites AC, Davidow LS, Woolf CJ, Rubin LL (2013) A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 12(6):713–726. doi:10.1016/j.stem.2013.04.003
Cuny GD (2012) Foreword: neurodegenerative diseases: challenges and opportunities. Futur Med Chem 4(13):1647–1649. doi:10.4155/fmc.12.123
Imaizumi Y, Okano H (2014) Modeling human neurological disorders with induced pluripotent stem cells. J Neurochem 129(3):388–399. doi:10.1111/jnc.12625
Maherali N, Hochedlinger K (2008) Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 3(6):595–605. doi:10.1016/j.stem.2008.11.008
Cundiff PE, Anderson SA (2011) Impact of induced pluripotent stem cells on the study of central nervous system disease. Curr Opin Genet Dev 21(3):354–361. doi:10.1016/j.gde.2011.01.008
Rashid ST, Alexander GJ (2013) Induced pluripotent stem cells: from Nobel Prizes to clinical applications. J Hepatol 58(3):625–629. doi:10.1016/j.jhep.2012.10.026
Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, Nishikawa S, Tanemura M, Mimori K, Tanaka F, Saito T, Nishimura J, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M (2011) Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 8(6):633–638. doi:10.1016/j.stem.2011.05.001
Malgrange B, Borgs L, Grobarczyk B, Purnelle A, Ernst P, Moonen G, Nguyen L (2011) Using human pluripotent stem cells to untangle neurodegenerative disease mechanisms. Cell Mol Life Sci CMLS 68(4):635–649. doi:10.1007/s00018-010-0557-6
Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S, Ikeda E, Yamanaka S, Miura K (2013) Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res 112(3):523–533. doi:10.1161/CIRCRESAHA.111.256149
Hargus G, Ehrlich M, Hallmann AL, Kuhlmann T (2014) Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development. Acta Neuropathol 127(2):151–173. doi:10.1007/s00401-013-1222-6
Hermann A, Storch A (2013) Induced neural stem cells (iNSCs) in neurodegenerative diseases. J Neural Transm 120(Suppl 1):S19–S25. doi:10.1007/s00702-013-1042-9
Anchan RM, Quaas P, Gerami-Naini B, Bartake H, Griffin A, Zhou YL, Day D, Eaton JL, George LL, Naber C, Turbe-Doan A, Park PJ, Hornstein MD, Maas RL (2011) Amniocytes can serve a dual function as a source of iPS cells and feeder layers. Hum Mol Genet 20(5):962–974
Liang G, Zhang Y (2013) Embryonic stem cell and induced pluripotent stem cell: an epigenetic perspective. Cell Res 23(1):49–69. doi:10.1038/cr.2012.175
Muller LU, Daley GQ, Williams DA (2009) Upping the ante: recent advances in direct reprogramming. Mol Ther J Am Soc Gene Ther 17(6):947–953. doi:10.1038/mt.2009.72
Liu J, Ashton MP, Sumer H, O’Bryan MK, Brodnicki TC, Verma PJ (2011) Generation of stable pluripotent stem cells from NOD mouse tail-tip fibroblasts. Diabetes 60(5):1393–1398. doi:10.2337/db10-1540
Wang P, Na J (2011) Mechanism and methods to induce pluripotency. Protein Cell 2(10):792–799. doi:10.1007/s13238-011-1107-1
Hong SG, Dunbar CE, Winkler T (2013) Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cells. Mol Ther J Am Soc Gene Ther 21(2):272–281. doi:10.1038/mt.2012.255
Kitada M, Wakao S, Dezawa M (2012) Muse cells and induced pluripotent stem cell: implication of the elite model. Cell Mol Life Sci CMLS 69(22):3739–3750. doi:10.1007/s00018-012-0994-5
Power C, Rasko JE (2011) Promises and challenges of stem cell research for regenerative medicine. Ann Intern Med 155(10):706–713. doi:10.7326/0003-4819-155-10-201111150-00010, W217
Jung YW, Hysolli E, Kim KY, Tanaka Y, Park IH (2012) Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies. Curr Opin Neurol 25(2):125–130. doi:10.1097/WCO.0b013e3283518226
Anastasia L, Pelissero G, Venerando B, Tettamanti G (2010) Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine. Cell Death Differ 17(8):1230–1237. doi:10.1038/cdd.2010.14
Wichterle H, Przedborski S (2010) What can pluripotent stem cells teach us about neurodegenerative diseases? Nat Neurosci 13(7):800–804. doi:10.1038/nn.2577
Robinton DA, Daley GQ (2012) The promise of induced pluripotent stem cells in research and therapy. Nature 481(7381):295–305. doi:10.1038/nature10761
Li M, Chen M, Han W, Fu X (2010) How far are induced pluripotent stem cells from the clinic? Ageing Res Rev 9(3):257–264. doi:10.1016/j.arr.2010.03.001
Gao A, Peng Y, Deng Y, Qing H (2013) Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases. Neuroscience 228:47–59. doi:10.1016/j.neuroscience.2012.09.076
Wong WT, Sayed N, Cooke JP (2013) Induced pluripotent stem cells: how they will change the practice of cardiovascular medicine. Methodist DeBakey Cardiovasc J 9(4):206–209
Byers B, Lee HL, Reijo Pera R (2012) Modeling Parkinson’s disease using induced pluripotent stem cells. Curr Neurol Neurosc Rep 12(3):237–242. doi:10.1007/s11910-012-0270-y
Lee G, Studer L (2011) Modelling familial dysautonomia in human induced pluripotent stem cells. Philos Trans R Soc Lond B Biol Sci 366(1575):2286–2296. doi:10.1098/rstb.2011.0026
Ito D, Okano H, Suzuki N (2012) Accelerating progress in induced pluripotent stem cell research for neurological diseases. Ann Neurol 72(2):167–174. doi:10.1002/ana.23596
Chen WW, Blurton-Jones M (2012) Concise review: can stem cells be used to treat or model Alzheimer’s disease? Stem Cells 30(12):2612–2618. doi:10.1002/stem.1240
Qiang L, Fujita R, Abeliovich A (2013) Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders. Neuron 78(6):957–969. doi:10.1016/j.neuron.2013.06.002
Vazin T, Ball KA, Lu H, Park H, Ataeijannati Y, Head-Gordon T, Poo MM, Schaffer DV (2013) Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: a model system to study neurotoxicity in Alzheimer’s disease. Neurobiol Dis 62C:62–72. doi:10.1016/j.nbd.2013.09.005
Auburger G, Klinkenberg M, Drost J, Marcus K, Morales-Gordo B, Kunz WS, Brandt U, Broccoli V, Reichmann H, Gispert S, Jendrach M (2012) Primary skin fibroblasts as a model of Parkinson’s disease. Mol Neurobiol 46(1):20–27. doi:10.1007/s12035-012-8245-1
Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Schule B, Dolmetsch RE, Langston W, Palmer TD, Pera RR (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8(3):267–280. doi:10.1016/j.stem.2011.01.013
Consortium HDi (2012) Induced pluripotent stem cells from patients with Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11(2):264–278. doi:10.1016/j.stem.2012.04.027
Zhang K, Yi F, Liu GH, Izpisua Belmonte JC (2012) Huntington’s disease: dancing in a dish. Cell Res 22(12):1627–1630. doi:10.1038/cr.2012.116
Guo X, Disatnik MH, Monbureau M, Shamloo M, Mochly-Rosen D, Qi X (2013) Inhibition of mitochondrial fragmentation diminishes Huntington’s disease-associated neurodegeneration. J Clin Invest 123(12):5371–5388. doi:10.1172/JCI70911
Cheng PH, Li CL, Chang YF, Tsai SJ, Lai YY, Chan AW, Chen CM, Yang SH (2013) miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. Am J Hum Genet 93(2):306–312. doi:10.1016/j.ajhg.2013.05.025
Laustriat D, Gide J, Peschanski M (2010) Human pluripotent stem cells in drug discovery and predictive toxicology. Biochem Soc Trans 38(4):1051–1057. doi:10.1042/BST0381051
Skibinski G, Finkbeiner S (2011) Drug discovery in Parkinson’s disease-update and developments in the use of cellular models. Int J High Throughput Screen 2011(2):15–25. doi:10.2147/IJHTS.S8681
Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A, Yoshida M, Nakahata T, Takahashi R, Marchetto MC, Gage FH, Yamanaka S, Inoue H (2012) Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 4(145):145ra104. doi:10.1126/scitranslmed.3004052
Rountree SD, Atri A, Lopez OL, Doody RS (2013) Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement J Alzheimers Assoc 9(3):338–345. doi:10.1016/j.jalz.2012.01.002
Jiang T, Yu JT, Tian Y, Tan L (2013) Epidemiology and etiology of Alzheimer’s disease: from genetic to non- genetic factors. Curr Alzheimer Res 10(8):852–867
Zhu XC, Yu JT, Jiang T, Wang P, Cao L, Tan L (2014) CR1 in Alzheimer’s disease. Mol Neurobiol. doi:10.1007/s12035-014-8723-8
Ooi L, Sidhu K, Poljak A, Sutherland G, O’Connor MD, Sachdev P, Munch G (2013) Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer’s disease. J Neural Transm 120(1):103–111. doi:10.1007/s00702-012-0839-2
Jiang T, Yu JT, Tan L (2012) Novel disease-modifying therapies for Alzheimer’s disease. J Alzheimers Dis JAD 31(3):475–492. doi:10.3233/JAD-2012-120640
Kiskinis E, Eggan K (2010) Progress toward the clinical application of patient-specific pluripotent stem cells. J Clin Invest 120(1):51–59. doi:10.1172/JCI40553
Wu SM, Hochedlinger K (2011) Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 13(5):497–505. doi:10.1038/ncb0511-497
Grskovic M, Javaherian A, Strulovici B, Daley GQ (2011) Induced pluripotent stem cells—opportunities for disease modelling and drug discovery. Nat Rev Drug Discov 10(12):915–929. doi:10.1038/nrd3577
Peng J, Zeng X (2011) The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases. Stem Cell Res Ther 2(4):32. doi:10.1186/scrt73
Imaizumi Y, Okano H (2013) Modeling human neurological disorders with induced pluripotent stem cells. J Neurochem. doi:10.1111/jnc.12625
Wojda U, Kuznicki J (2013) Alzheimer’s disease modeling: ups, downs, and perspectives for human induced pluripotent stem cells. J Alzheimers Dis JAD 34(3):563–588. doi:10.3233/JAD-121984
Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ (2012) A human stem cell model of early Alzheimer’s disease pathology in Down syndrome. Sci Transl Med 4(124):124ra129. doi:10.1126/scitranslmed.3003771
Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE, Muffat J, Mitalipova M, Pluth MD, Jui NT, Schule B, Lippard SJ, Tsai LH, Krainc D, Buchwald SL, Jaenisch R, Lindquist S (2013) Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science 342(6161):983–987. doi:10.1126/science.1245296
Martinez-Morales PL, Liste I (2012) Stem cells as in vitro model of Parkinson’s disease. Stem Cells Int 2012:980941. doi:10.1155/2012/980941
Zuo L, Motherwell MS (2013) The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson’s disease. Gene 532(1):18–23. doi:10.1016/j.gene.2013.07.085
Yao J, Mu Y, Gage FH (2012) Neural stem cells: mechanisms and modeling. Protein Cell 3(4):251–261. doi:10.1007/s13238-012-2033-6
Compagnucci C, Nizzardo M, Corti S, Zanni G, Bertini E (2013) In vitro neurogenesis: development and functional implications of iPSC technology. Cell Mol Life Sci CMLS. doi:10.1007/s00018-013-1511-1
Xu L, Tan YY, Ding JQ, Chen SD (2010) The iPS technique provides hope for Parkinson’s disease treatment. Stem Cell Rev 6(3):398–404. doi:10.1007/s12015-010-9145-2
Gibson SA, Gao GD, McDonagh K, Shen S (2012) Progress on stem cell research towards the treatment of Parkinson’s disease. Stem Cell Res Ther 3(2):11. doi:10.1186/scrt102
Pu J, Jiang H, Zhang B, Feng J (2012) Redefining Parkinson’s disease research using induced pluripotent stem cells. Curr Neurol Neurosci Rep 12(4):392–398. doi:10.1007/s11910-012-0288-1
Sommer CA, Mostoslavsky G (2013) The evolving field of induced pluripotency: recent progress and future challenges. J Cell Physiol 228(2):267–275. doi:10.1002/jcp.24155
Miller JD, Ganat YM, Kishinevsky S, Bowman RL, Liu B, Tu EY, Mandal PK, Vera E, Shim JW, Kriks S, Taldone T, Fusaki N, Tomishima MJ, Krainc D, Milner TA, Rossi DJ, Studer L (2013) Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13(6):691–705. doi:10.1016/j.stem.2013.11.006
Brennand KJ (2013) Inducing cellular aging: enabling neurodegeneration-in-a-dish. Cell Stem Cell 13(6):635–636. doi:10.1016/j.stem.2013.11.017
An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Melov S, Ellerby LM (2012) Genetic correction of Huntington’s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11(2):253–263. doi:10.1016/j.stem.2012.04.026
Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, Shim SH, Choi C, Chang DJ, Kwon J, Oh SH, Shin DA, Kim HS, Do JT, Lee DR, Kim M, Kang KS, Daley GQ, Brundin P, Song J (2012) Neuronal properties, in vivo effects, and pathology of a Huntington’s disease patient-derived induced pluripotent stem cells. Stem Cells 30(9):2054–2062. doi:10.1002/stem.1135
Nicoleau C, Viegas P, Peschanski M, Perrier AL (2011) Human pluripotent stem cell therapy for Huntington’s disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington’s disease: technical, immunological, and safety challenges. Neurother J Am Soc Exp NeuroTher 8(4):562–576. doi:10.1007/s13311-011-0079-4
Xu XH, Zhong Z (2013) Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Acta Pharmacol Sin 34(6):755–764. doi:10.1038/aps.2013.63
Reinhart PH, Kaltenbach LS, Essrich C, Dunn DE, Eudailey JA, DeMarco CT, Turmel GJ, Whaley JC, Wood A, Cho S, Lo DC (2011) Identification of anti-inflammatory targets for Huntington’s disease using a brain slice-based screening assay. Neurobiol Dis 43(1):248–256. doi:10.1016/j.nbd.2011.03.017
Benraiss A, Goldman SA (2011) Cellular therapy and induced neuronal replacement for Huntington’s disease. Neurother J Am Soc Exp NeuroTher 8(4):577–590. doi:10.1007/s13311-011-0075-8
Sareen D, O’Rourke JG, Meera P, Muhammad AK, Grant S, Simpkinson M, Bell S, Carmona S, Ornelas L, Sahabian A, Gendron T, Petrucelli L, Baughn M, Ravits J, Harms MB, Rigo F, Bennett CF, Otis TS, Svendsen CN, Baloh RH (2013) Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med 5(208):208ra149. doi:10.1126/scitranslmed.3007529
Aliaga L, Lai C, Yu J, Chub N, Shim H, Sun L, Xie C, Yang WJ, Lin X, O’Donovan MJ, Cai H (2013) Amyotrophic lateral sclerosis-related VAPB P56S mutation differentially affects the function and survival of corticospinal and spinal motor neurons. Hum Mol Genet 22(21):4293–4305. doi:10.1093/hmg/ddt279
Inoue H (2010) Neurodegenerative disease-specific induced pluripotent stem cell research. Exp Cell Res 316(16):2560–2564. doi:10.1016/j.yexcr.2010.04.022
Abeliovich A, Doege CA (2009) Reprogramming therapeutics: iPS cell prospects for neurodegenerative disease. Neuron 61(3):337–339. doi:10.1016/j.neuron.2009.01.024
Saporta MA, Grskovic M, Dimos JT (2011) Induced pluripotent stem cells in the study of neurological diseases. Stem Cell Res Ther 2(5):37. doi:10.1186/scrt78
Liu W, Deng Y, Liu Y, Gong W, Deng W (2013) Stem cell models for drug discovery and toxicology studies. J Biochem Mol Toxicol 27(1):17–27. doi:10.1002/jbt.21470
Roshan R, Ghosh T, Scaria V, Pillai B (2009) MicroRNAs: novel therapeutic targets in neurodegenerative diseases. Drug Discov Today 14(23–24):1123–1129. doi:10.1016/j.drudis.2009.09.009
Duan L, Bhattacharyya BJ, Belmadani A, Pan L, Miller RJ, Kessler JA (2014) Stem cell derived basal forebrain cholinergic neurons from Alzheimer’s disease patients are more susceptible to cell death. Mol Neurodegener 9(1):3. doi:10.1186/1750-1326-9-3
Bellin M, Marchetto MC, Gage FH, Mummery CL (2012) Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol 13(11):713–726. doi:10.1038/nrm3448
Zinman L, Cudkowicz M (2011) Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol 10(5):481–490. doi:10.1016/S1474-4422(11)70024-2
Kaye JA, Finkbeiner S (2013) Modeling Huntington’s disease with induced pluripotent stem cells. Mol Cell Neurosci 56:50–64. doi:10.1016/j.mcn.2013.02.005
Hamasaki M, Hashizume Y, Yamada Y, Katayama T, Hohjoh H, Fusaki N, Nakashima Y, Furuya H, Haga N, Takami Y, Era T (2012) Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification. Stem Cells 30(11):2437–2449. doi:10.1002/stem.1221
Yung JS, Tam PK, Ngan ES (2013) Pluripotent stem cell for modeling neurological diseases. Exp Cell Res 319(2):177–184. doi:10.1016/j.yexcr.2012.11.007
Mercola M, Colas A, Willems E (2013) Induced pluripotent stem cells in cardiovascular drug discovery. Circ Res 112(3):534–548. doi:10.1161/CIRCRESAHA.111.250266
Ramsden N, Perrin J, Ren Z, Lee BD, Zinn N, Dawson VL, Tam D, Bova M, Lang M, Drewes G, Bantscheff M, Bard F, Dawson TM, Hopf C (2011) Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson’s disease-related toxicity in human neurons. ACS Chem Biol 6(10):1021–1028. doi:10.1021/cb2002413
Prilutsky D, Palmer NP, Smedemark-Margulies N, Schlaeger TM, Margulies DM, Kohane IS (2014) iPSC-derived neurons as a higher-throughput readout for autism: promises and pitfalls. Trends Mol Med 20(2):91–104. doi:10.1016/j.molmed.2013.11.004
Engle SJ, Vincent F (2013) Small molecule screening in human induced pluripotent stem cell-derived terminal cell types. J Biol Chem. doi:10.1074/jbc.R113.529156
Mackay-Sim A (2013) Patient-derived stem cells: pathways to drug discovery for brain diseases. Front Cell Neurosci 7:29. doi:10.3389/fncel.2013.00029
Mancini C, Roncaglia P, Brussino A, Stevanin G, Lo Buono N, Krmac H, Maltecca F, Gazzano E, Bartoletti Stella A, Calvaruso MA, Iommarini L, Cagnoli C, Forlani S, Le Ber I, Durr A, Brice A, Ghigo D, Casari G, Porcelli AM, Funaro A, Gasparre G, Gustincich S, Brusco A (2013) Genome-wide expression profiling and functional characterization of SCA28 lymphoblastoid cell lines reveal impairment in cell growth and activation of apoptotic pathways. BMC Med Genet 6:22. doi:10.1186/1755-8794-6-22
Ryan SD, Dolatabadi N, Chan SF, Zhang X, Akhtar MW, Parker J, Soldner F, Sunico CR, Nagar S, Talantova M, Lee B, Lopez K, Nutter A, Shan B, Molokanova E, Zhang Y, Han X, Nakamura T, Masliah E, Yates JR 3rd, Nakanishi N, Andreyev AY, Okamoto S, Jaenisch R, Ambasudhan R, Lipton SA (2013) Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. Cell 155(6):1351–1364. doi:10.1016/j.cell.2013.11.009
Jain S, van Kesteren RE, Heutink P (2012) High content screening in neurodegenerative diseases. J Visualized Exp JoVE 59:e3452. doi:10.3791/3452
Landgren H, Sartipy P (2014) Can stem-cell-derived models revolutionize drug discovery? Expert Opin Drug Discov 9(1):9–13. doi:10.1517/17460441.2014.867945
Gladstone M, Su TT (2011) Chemical genetics and drug screening in Drosophila cancer models. J Genet Genomics Yi chuan xue bao 38(10):497–504. doi:10.1016/j.jgg.2011.09.003
Calamini B, Lo DC, Kaltenbach LS (2013) Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration. Neurother J Am Soc Exp NeuroTher 10(3):400–415. doi:10.1007/s13311-013-0195-4
Sendtner M (2010) Therapy development in spinal muscular atrophy. Nat Neurosci 13(7):795–799. doi:10.1038/nn.2565
Hasson SA, Kane LA, Yamano K, Huang CH, Sliter DA, Buehler E, Wang C, Heman-Ackah SM, Hessa T, Guha R, Martin SE, Youle RJ (2013) High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature 504(7479):291–295. doi:10.1038/nature12748
Wang T, Warren ST, Jin P (2013) Toward pluripotency by reprogramming: mechanisms and application. Protein Cell 4(11):820–832. doi:10.1007/s13238-013-3074-1
Zhao J, Jiang WJ, Sun C, Hou CZ, Yang XM, Gao JG (2013) Induced pluripotent stem cells: origins, applications, and future perspectives. J Zhejiang Univ Sci B 14(12):1059–1069. doi:10.1631/jzus.B1300215
Wobus AM, Loser P (2011) Present state and future perspectives of using pluripotent stem cells in toxicology research. Arch Toxicol 85(2):79–117. doi:10.1007/s00204-010-0641-6
Rao M, Gottesfeld JM (2014) Introduction to thematic minireview series: development of human therapeutics based on induced pluripotent stem cell (iPSC) technology. J Biol Chem 289(8):4553–4554. doi:10.1074/jbc.R113.543652
Gunaseeli I, Doss MX, Antzelevitch C, Hescheler J, Sachinidis A (2010) Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. Curr Med Chem 17(8):759–766
Kumar KK, Aboud AA, Bowman AB (2012) The potential of induced pluripotent stem cells as a translational model for neurotoxicological risk. Neurotoxicology 33(3):518–529. doi:10.1016/j.neuro.2012.02.005
Zhang R, Zhang LH, Xie X (2013) iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery. Acta Pharmacol Sin 34(6):765–776. doi:10.1038/aps.2013.21
Scott CW, Peters MF, Dragan YP (2013) Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol Lett 219(1):49–58. doi:10.1016/j.toxlet.2013.02.020
Jongkamonwiwat N, Noisa P (2013) Biomedical and clinical promises of human pluripotent stem cells for neurological disorders. BioMed Res Int 2013:656531. doi:10.1155/2013/656531
Sandoe J, Eggan K (2013) Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat Neurosci 16(7):780–789
Sun X, Fu X, Han W, Zhao Y, Liu H (2010) Can controlled cellular reprogramming be achieved using microRNAs? Ageing Res Rev 9(4):475–483. doi:10.1016/j.arr.2010.06.002
Lian Q, Chow Y, Esteban MA, Pei D, Tse HF (2010) Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases. Thromb Haemost 104(1):39–44. doi:10.1160/TH10-05-0269
Yamanaka S (2012) Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10(6):678–684. doi:10.1016/j.stem.2012.05.005
Nie B, Wang H, Laurent T, Ding S (2012) Cellular reprogramming: a small molecule perspective. Curr Opin Cell Biol 24(6):784–792. doi:10.1016/j.ceb.2012.08.010
Zhou W, Freed CR (2009) Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 27(11):2667–2674. doi:10.1002/stem.201
Yusa K, Rad R, Takeda J, Bradley A (2009) Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 6(5):363–369. doi:10.1038/nmeth.1323
Mattis VB, Svendsen CN (2011) Induced pluripotent stem cells: a new revolution for clinical neurology? Lancet Neurol 10(4):383–394. doi:10.1016/S1474-4422(11)70022-9
Wu K, Ding J, Chen C, Sun W, Ning BF, Wen W, Huang L, Han T, Yang W, Wang C, Li Z, Wu MC, Feng GS, Xie WF, Wang HY (2012) Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 56(6):2255–2267. doi:10.1002/hep.26007
Abdullah AI, Pollock A, Sun T (2012) The path from skin to brain: generation of functional neurons from fibroblasts. Mol Neurobiol 45(3):586–595. doi:10.1007/s12035-012-8277-6
Nakamura M, Okano H (2013) Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. Cell Res 23(1):70–80. doi:10.1038/cr.2012.171
Hanley J, Rastegarlari G, Nathwani AC (2010) An introduction to induced pluripotent stem cells. Br J Haematol 151(1):16–24. doi:10.1111/j.1365-2141.2010.08296.x
Rajamohan D, Matsa E, Kalra S, Crutchley J, Patel A, George V, Denning C (2013) Current status of drug screening and disease modelling in human pluripotent stem cells. BioEssays News Rev Mol Cell Dev Biol 35(3):281–298. doi:10.1002/bies.201200053
Rada-Iglesias A, Wysocka J (2011) Epigenomics of human embryonic stem cells and induced pluripotent stem cells: insights into pluripotency and implications for disease. Genome Med 3(6):36. doi:10.1186/gm252
Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China to L.T. (81171209 and 81371406) and J.T.Y. (81000544), grants from the Shandong Provincial Natural Science Foundation to L.T. (ZR2011HZ001) and J.T.Y. (ZR2010HQ004), the Medicine and Health Science Technology Development Project of Shandong Province to L.T. (2011WSA02018) and J.T.Y. (2011WSA02020), and the Innovation Project for Postgraduates of Jiangsu Province to T.J. (CXLX13_561).
Conflict of Interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Cao, L., Tan, L., Jiang, T. et al. Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases. Mol Neurobiol 52, 244–255 (2015). https://doi.org/10.1007/s12035-014-8867-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-014-8867-6